Evidence map›Paper›PMID 26779858›Full record

ReviewCurrent opinion in psychiatry2016

The importance of understanding cognitive trajectories: the case of 22q11.2 deletion syndrome.

Ann Swillen

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Psychiatric disorders and autism in young children with 22q11.2 deletion syndrome compared to children with idiopathic autism.European psychiatry : the journal of the Association of European Psychiatrists · 2019
    Article
  11. Neurodevelopmental outcome in 22q11.2 deletion syndrome and management.American journal of medical genetics. Part A · 2018
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ann SwillenaDepartment of Human Genetics bDepartment of Rehabilitation Sciences, KU Leuven cCenter of Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium.
Center for Human Genetics · US

Funding

"4/5 International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome"U01MH101722 · NIMH · KATHOLIEKE UNIVERSITEIT LEUVEN · PI SWILLEN, ANN · 2013 to 2016
$1.3M
NIMH NIH HHS U01 MH101722
6 · The paper itself

Abstract

purpose of reviewThe 22q11.2 deletion syndrome (velo-cardio-facial syndrome or DiGeorge syndrome) is the most common known contiguous gene deletion syndrome, and is associated with neurodevelopmental problems and diverse neuropsychiatric disorders across the life span. In this review, we discuss the wide variability in intelligence, the developmental phenotypic transitions regarding cognitive development (intelligence) from preschool to adolescence, and the importance of understanding these cognitive trajectories in 22q11.2 deletion syndrome for care/management and research. RECENT

findingsLongitudinal data on the cognitive development of children and adolescents with 22q11.2 deletion syndrome reveal divergent cognitive trajectories. A decline in verbal intelligence quotient precedes the onset of psychosis in 22q11.2 deletion syndrome. SUMMARY: Understanding these cognitive trajectories is important since it can guide clinicians to develop adequate support, tailored remediation, and psychiatric care and individualized follow-up.

Indexed as

Child DevelopmentCognitionIntelligenceAdolescentChildChild, PreschoolDiGeorge SyndromeHumansPsychotic DisordersRisk Factors

Identifiers

PMID26779858
PMCPMC5414032
OpenAlexW2418069531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.